Research on the Amyloid in Alzheimer’s Disease
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Aging".
Deadline for manuscript submissions: 31 January 2025 | Viewed by 1100
Special Issue Editor
Interests: Alzheimer’s disease-associated neuroinflammation and neurodegeneration; tau hyperphosphorylation; neurotoxic astrocytes; brain injury; ischemic stroke; microglial dysfunction
Special Issue Information
Dear Colleagues,
Alzheimer’s disease (AD) is a globally prevalent progressive and neurodegenerative brain disorder, characterized by amyloid plaques and tau tangles leading to cognitive decline. Recent research on the amyloid in AD, including the “amyloid clock” biomarker, has made significant strides. While there is still no cure for AD, the recent FDA-approved anti-amyloid drugs aducanumab and lecanemab reduce its symptoms. However, there is a need to understand the interaction between neurons and non-neurons, which contributes to an imbalance between the production and clearance of the amyloid in AD, better. AD-patient-derived inducible pluripotent stem cells (iPSCs) can differentiate into various types of neurons, non-neurons, and brain organoids in vitro and in in vivo models, recapitulating the AD pathology in relevant cells.
This Special Issue will examine novel amyloid-associated mechanisms and improved biomarkers for AD; the amyloid’s effect on the AD brain network; AD patient iPSC-derived neurons, non-neurons, and brain organoids; and in vivo models investigating the role of the amyloid in AD.
Yours faithfully,
Dr. Archna Sharma
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- amyloid
- Alzheimer’s disease
- amyloid biomarkers
- brain network
- anti-amyloid immunotherapy
- inducible pluripotent stem cells
- neuron and non-neuron differentiation
- brain organoids
- amyloidopathy animal models
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
